Qiagen, Applied Biosystems settle patent dispute
This article was originally published in Clinica
Executive Summary
Qiagen and Applied Biosystems have settled a patent dispute over real-time PCR detection technology, clearing all litigation between the two firms. Last year, Applied Biosystems filed a complaint in Germany against Corbett which alleged that the latter's Rotor-Gene real-time PCR cycler technology infringed patents that Applied Biosystems held for real-time thermal cycler instruments. Corbett responded by filing a separate suit against Applied Biosystems in California. In June 2008, Qiagen bought Corbett for $135m (see Clinica No 1313, p 3), thus assuming responsibility for Corbett’s lawsuit. As part of the resolution, Corbett has taken a license from Foster City, California-based Applied Biosystems, which will enable it to sell its Rotor-Gene for all fields, including molecular research and human and animal in vitro diagnostics purposes. Financial terms of the settlement were not disclosed.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals